Bronchoalveolar cytokine profile differentiates Pulmonary Langerhans cell histiocytosis patients from other smoking-related interstitial lung diseases

Pulmonary Langerhans cell histiocytosis (PLCH) is a rare interstitial lung disease (ILD) associated with smoking, whose definitive diagnosis requires the exclusion of other forms of ILD and a compatible surgical lung biopsy. Bronchoalveolar lavage (BAL) is commonly proposed for the diagnosis of ILD,...

Full description

Saved in:
Bibliographic Details
Published in:Respiratory research 2023-12, Vol.24 (1), p.320-320, Article 320
Main Authors: Barril, Silvia, Acebo, Paloma, Millan-Billi, Paloma, Luque, Alfonso, Sibila, Oriol, Tarín, Carlos, Tazi, Abdellatif, Castillo, Diego, Hortelano, Sonsoles
Format: Article
Language:English
Subjects:
Algorithms
Alveoli
Analysis
Antibodies
Antigens
Autoimmune diseases
Biopsy
Bronchoalveolar lavage
Bronchus
Care and treatment
Cell differentiation
Chemokines
Clustering
CXCL10 protein
Cytokines
Datasets
Diagnosis
Fibrosis
Granulomas
Growth factors
Health aspects
Histiocytosis
Inflammation
Inflammatory profile
Interstitial lung disease
IP-10 protein
Laboratories
Langerhans-cell histiocytosis
Lavage
Leptin
Lung diseases
Network analysis
Oncostatin M
Prediction models
Principal components analysis
Protein-protein interactions
Proteins
Pulmonary fibrosis
Pulmonary Langerhans cell histiocytosis
Respiratory function
Risk factors
Smoking
Software
Statistical analysis
Testing
Tumor necrosis factor-TNF
Viral antibodies
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pulmonary Langerhans cell histiocytosis (PLCH) is a rare interstitial lung disease (ILD) associated with smoking, whose definitive diagnosis requires the exclusion of other forms of ILD and a compatible surgical lung biopsy. Bronchoalveolar lavage (BAL) is commonly proposed for the diagnosis of ILD, including PLCH, but the diagnostic value of this technique is limited. Here, we have analyzed the levels of a panel of cytokines and chemokines in BAL from PLCH patients, in order to identify a distinct immune profile to discriminate PLCH from other smoking related-ILD (SR-ILD), and comparing the results with idiopathic pulmonary fibrosis (IPF) as another disease in which smoking is considered a risk factor. BAL samples were collected from thirty-six patients with different ILD, including seven patients with PLCH, sixteen with SR-ILD and thirteen with IPF. Inflammatory profiles were analyzed using the Human Cytokine Membrane Antibody Array. Principal component analysis (PCA) was performed to reduce dimensionality and protein-protein interaction (PPI) network analysis using STRING 11.5 database were conducted. Finally, Random forest (RF) method was used to build a prediction model. We have found significant differences (p 
ISSN:1465-993X
1465-9921
1465-993X
1465-9921
DOI:10.1186/s12931-023-02622-z